Breakthrough in Cancer Gene Therapy: Eltrombopag Shows Promise in Treating Fanconi Anemia

Researchers at the Pediatric University Hospital in Madrid, Spain have reported a significant breakthrough in the treatment of Fanconi anemia, a rare and debilitating genetic disorder that leads to bone marrow failure and an increased risk of cancer. According to a recent study published in Frontiers in Pediatrics, the researchers have found that eltrombopag, a medication that stimulates platelet production, can also promote DNA repair in Fanconi anemia stem cells and potentially cure the disease. The study involved a patient with somatic mosaicism, who achieved transfusion independence and avoided the need for a bone marrow transplant, as well as two patients who had previously received gene therapy but had low numbers of corrected cells. These patients showed a marked increase in corrected cells during treatment.

Key Takeaways:

• Eltrombopag has been found to stimulate trilineage hematopoiesis in aplastic anemia and promote DNA repair in Fanconi anemia hematopoietic stem cells (HSCs).
• The medication has demonstrated efficacy in treating Fanconi anemia, a disease characterized by bone marrow failure, hematologic and solid malignancies, and diverse clinical features.
• Treatment with eltrombopag has the potential to cure Fanconi anemia, as evidenced by the patient with somatic mosaicism who achieved transfusion independence and avoided the need for a bone marrow transplant.
• The researchers involved in the study are from the Pediatric Hematology and Oncology Department and the Foundation for the Biomedical Research and Biomedical Network Research Center for Rare Diseases (CIBERER) at the Pediatric University Hospital Nino Jesus in Madrid, Spain.
• The study has significant implications for the treatment of Fanconi anemia, a disease that has few effective treatment options, and highlights the potential of eltrombopag as a preventive and therapeutic agent.

Statistics:

• According to the study, the patient with somatic mosaicism achieved transfusion independence after treatment with eltrombopag.
• The two patients who had previously received gene therapy but had low numbers of corrected cells showed a marked increase in corrected cells during treatment.
• Approximately 1 in 100,000 children are born with Fanconi anemia, a condition characterized by bone marrow failure and an increased risk of cancer.

Sources:

• Case Report: Eltrombopag in mosaic and gene therapy-treated patients with Fanconi anemia. Frontiers in Pediatrics, 2025,13.
• NewsRx. Pediatric University Hospital Researchers Describe New Findings in Cancer Gene Therapy (Case Report: Eltrombopag in mosaic and gene therapy-treated patients with Fanconi anemia). Biotech Week. August 27, 2025; p 56.